Research Progress of Immune Checkpoints Blockade in the Tumor Immunotherapy

doi:10.3969/j.issn.1007-9572.2016.26.025

Abstract

Abstract: Immune checkpoints are the key factors in maintaining self tolerance and regulating the immune response signal pathway，and play a role in the intervention and influence of T cell immunologic response，through which protect the body from autoimmune and inflammatory injury.The dysfunction of these immune checkpoints will lead to tumor resistance and eventually the tumor cells can escape from the killing of the immune system.Immune checkpoints blockade can activate antitumor immune responses，identify and kill tumor cells，which has become the new hope of future antitumor treatment.The paper attaches importance to the review of the latest developments and future research prospects of the immune checkpoints blockade in tumor immune treatment.

Key words: Immune checkpoints blockade, Immunotherapy, Tumor-immunity cycle, CTLA-4, PD-1, PD-L1

摘要： 　　免疫卡控点是维持自身耐受性和调节免疫反应信号通路的关键因子，通过干预与影响T细胞免疫应答发挥作用，保护机体免于自身免疫和炎症的伤害。当免疫卡控点无法正常发挥功能时，会引起肿瘤耐受，使得肿瘤细胞逃过免疫系统的追杀。免疫卡控点阻断疗法可以激活抗肿瘤免疫反应，识别并杀伤肿瘤细胞，已经成为未来抗肿瘤治疗的新希望。本文重点就近年来免疫卡控点阻断疗法在肿瘤免疫治疗中的最新进展及未来的研究前景进行综述。

关键词: 免疫卡控点阻断, 免疫治疗, 肿瘤-免疫循环, CTLA-4, PD-1, PD-L1

DAI Huan-yu, LU Shun, YE Xiang-yun, MA Yan, ZHAO Da. Research Progress of Immune Checkpoints Blockade in the Tumor Immunotherapy[J]. Chinese General Practice, 2016, 19(26): 3248-3252.

代环宇, 陆舜, 叶翔赟, 马岩, 赵达. 免疫卡控点阻断疗法在肿瘤免疫治疗中的研究进展[J]. 中国全科医学, 2016, 19(26): 3248-3252.

References

［1］FITZMAURICE C，DICKER D，PAIN A，et al.The global burden of cancer 2013［J］.JAMA Oncol，2015，1（4）：505-527. ［2］HANAHAN D，WEINBERG R A.Hallmarks of cancer：the next generation［J］.Cell，2011，144（5）：646-674. ［3］MIZOGUCHI H，O’SHEA J J，LONGO D L，et al.Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice［J］.Science，1992，258（5089）：1795-1798. ［4］FACCIABENE A，MOTZ G T，COUKOS G.T-regulatory cells：key players in tumor immune escape and angiogenesis［J］.Cancer Res，2012，72（9）：2162-2171. ［5］TOPALIAN S L，WEINER G J，PARDOLL D M.Cancer immunotherapy comes of age［J］.J Clin Oncol，2011，29（36）：4828-4836. ［6］MELLMAN I，COUKOS G，DRANOFF G.Cancer immunotherapy comes of age［J］.Nature，2011，480（7378）：480-489. ［7］SUNDAR R，SOONG R，CHO B C，et al.Immunotherapy in the treatment of non-small cell lung cancer［J］.Lung Cancer，2014，85（2）：101-109. ［8］CHEN D S，MELLMAN I.Oncology meets immunology：the cancer-immunity cycle［J］.Immunity，2013，39（1）：1-10. ［9］BRAHMER J R.Harnessing the immune system for the treatment of non-small-cell lung cancer［J］.J Clin Oncol，2013，31（8）：1021-1028. ［10］HODI F S，O’DAY S J，MCDERMOTT D F，et al.Improved survival with ipilimumab in patients with metastatic melanoma［J］.N Engl J Med，2010，363（8）：711-723. ［11］LEDFORD H.Melanoma drug wins US approval［J］.Nature，2011，471（7340）：561. ［12］KWON E D，DRAKE C G，SCHER H I，et al.Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy（CA184-043）：a multicentre，randomised，double-blind，phase 3 trial［J］.Lancet Oncol，2014，15（7）：700-712. ［13］SANGRO B，GOMEZ-MARTIN C，DE LA MATA M，et al.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C［J］.J Hepatol，2013，59（1）：81-88. ［14］CALABR L，MORRA A，FONSATTI E，et al.Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma：an open-label，single-arm，phase 2 study［J］.Lancet Respir Med，2015，3（4）：301-309. ［15］JILLIAN D.FDA grants AstaZeneca’s Tremelimumab orphan drug status for mesothelioma［EB/OL］.（2015-04-17）［2015-10-19］.http：//www.mesothelioma.com/news/2015/04/fda-grants-astrazenecas-tremelimumab-orphan-drug-status-for-mesothelioma.htm. ［16］DONG H，STROME S E，SALOMAO D R，et al.Tumor-associated B7-H1 promotes T-cell apoptosis：a potential mechanism of immune evasion［J］.Nat Med，2002，8（8）：793-800. ［17］IWAI Y，ISHIDA M，TANAKA Y，et al.Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade［J］.Proc Natl Acad Sci U S A，2002，99（19）：12293-12297. ［18］LANDI L，CAPPUZZO F.Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer［J］.Ann Transl Med，2015，3（3）：32. ［19］RIZVI N A，MAZIRES J，PLANCHARD D，et al.Activity and safety of nivolumab，an anti-PD-1 immune checkpoint inhibitor，for patients with advanced，refractory squamous non-small-cell lung cancer（CheckMate 063）：a phase 2，single-arm trial［J］.Lancet Oncol，2015，16（3）：257-265. ［20］FDA expands approved use of Opdivo to treat lung cancer［EB/OL］.（2015-03-04）［2015-10-19］.http：//www.fda.gov/News Events/Newsroom/Press Announcements/ucm436534.htm. ［21］KAREN R，BRAHMER J R，SPIGEL D R，et al.Phase 3，Randomized trial（CheckMate 017）of nivolumab（NIVO） vs docetaxel in advanced squamous（SQ）cell non-small cell lung cancer（NSCLC）［C］//WCLC Abstracts.Denver：J Thorac Oncol，2015：ORAL02.01. ［22］LEORA H，RIZVI N A，MAZIRES J，et al.Longer-term follow-up of a phase 2 study（CheckMate 063）of nivolumab in patients with advanced，refractory squamous non-small cell lung cancer［C］//WCLC Abstracts.Denver：J Thorac Oncol，2015：ORAL02.03. ［23］TOPALIAN S L，SZNOL M，MCDERMOTT D F，et al.Survival，durable tumor remission，and long-term safety in patients with advanced melanoma receiving nivolumab［J］.J Clin Oncol，2014，32（10）：1020-1030. ［24］SZNOL M，KLUGER H M，RIZVI N A，et al.Survival，response duration，and activity by BRAF mutation（MT）status of nivolumab（NIVO，anti-PD-1，BMS-936558，ONO-4538）and ipilimumab（IPI）concurrent therapy in advanced melanoma［C］//ASCO Meeting Abstracts.Chicago：J Clin Oncol，2014：LBA9003. ［25］ROBERT C，LONG G V，BRADY B，et al.Nivolumab in previously untreated melanoma without BRAF mutation［J］.N Engl J Med，2015，372（4）：320-330. ［26］FDA approves Opdivo for advanced melanoma［EB/OL］.（2014-12-22）［2015-10-19］.http：//www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm. ［27］FDA approves Keytruda for advanced melanoma［EB/OL］.（2014-09-04）［2015-10-19］.http：//www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm. ［28］GARON E B，RIZVI N A，HUI R，et al.Pembrolizumab for the treatment of non-small-cell lung cancer［J］.N Engl J Med，2015，372（21）：179-188. ［29］HAMID O，ROBERT C，DAUD A，et al.Safety and tumor responses with lambrolizumab（anti-PD-1）in melanoma［J］.N Engl J Med，2013，369（2）：134-144. ［30］GARON E，BALMANOUKIAN A，HAMID O，et al.Preliminary clinical safety and activity of MK-3475 mono-therapy for the treatment of previously treated patients with non-small cell lung cancer［C］//WCLC Abstracts.Sydney：J Thorac Oncol，2013：MO18.02. ［31］SORIA J，CRUZ C，BAHLEDA R，et al.Clinical activity， safety and biomarkers of PD-L1 blockade in non-small cell lung cancer（NSCLC）：additional analyses from a clinical study of the engineered antibody MPDL3280A （anti-PDL1）［C］//ESMO Abstracts.Amsterdam：Ann Oncol，2013：3408. ［32］SPIRA A I.Efficacy，safety and predictive biomarker results from a randomized phase Ⅱ study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC（POPLAR）［C］//ASCO Meeting Abstracts.Chicago：J Clin Oncol，2015：8010. ［33］KHLEIF S，LUTZKY J，SEGAL N，et al.MEDI4736，an anti-PD-L1 antibody with modified Fc domain：preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors［C］//ESMO Abstracts.Amsterdam：Ann Oncol，2013：802. ［34］RIZVI N A.Safety and clinical activity of MEDI4736，an anti-programmed cell death-ligand 1（PD-L1）antibody，in patients with non-small cell lung cancer（NSCLC）［C］//ASCO Meeting Abstracts.Chicago：J Clin Oncol，2015：8032. ［35］MONNEY L，SABATOS C A，GAGLIA J L，et al.Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease［J］.Nature，2002，415（6871）：536-541. ［36］SAKUISHI K，APETOH L，SULLIVAN J M，et al.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity［J］.J Exp Med，2010，207（10）：2187-2194. ［37］ZHOU Q，MUNGER M E，VEENSTRA R G，et al.Coexpression of Tim-3 and PD-1 identifies a CD+8 T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia［J］.Blood，2011，117（17）：4501-4510. ［38］WEINBERG A D，RIVERA M M，PRELL R，et al.Engagement of the OX-40 receptor in vivo enhances antitumor immunity［J］.J Immunol，2000，164（4）：2160-2169. ［39］RONCHETTI S，NOCENTINI G，RICCARDI C，et al.Role of GITR in activation response of T lymphocytes［J］.Blood，2002，100（1）：350-352. ［40］SABEL M S，YAMADA M，KAWAGUCHI Y，et al.CD40 expression on human lung cancer correlates with metastatic spread［J］.Cancer Immunol Immunother，2000，49（2）：101-108. ［41］VON SCHEIDT B，LEUNG P S，YONG M C，et al.Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases［J］.Cancer Res，2014，74（9）：2412-2421. ［42］SUNTHARALINGAM G，PERRY M R，WARD S，et al.Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412［J］.N Engl J Med，2006，355（10）：1018-1028. ［43］AMITA P.Phase 1 study of pembrolizumab（pembro；MK-3475）plus ipilimumab（IPI）as second-line therapy foradvanced non-small cell lung cancer（NSCLC）：KEYNOTE-021 cohort D［C］//ASCO Meeting Abstracts.Chicago：J Clin Oncol，2015：8011. ［44］ANTONIA S J.Phase Ⅰb study of MEDI4736，a programmed cell death ligand-1（PD-L1） antibody，in combination with tremelimumab，a cytotoxic T-lymphocyte-associated protein-4（CTLA-4） antibody，in patients（pts） with advanced NSCLC［C］//ASCO Meeting Abstracts.Chicago：J Clin Oncol，2015：3014. ［45］PAZ-ARES L.Phase Ⅲ，randomized trial（CheckMate 057）of nivolumab（NIVO）versus docetaxel（DOC）in advanced non-squamous cell（non-SQ）non-small cell lung cancer（NSCLC）［C］//ASCO Meeting Abstracts.Chicago：J Clin Oncol，2015：LBA109.

[1]	YANG Haifei, SUN Wu, WU Cheng, REN Wei, LI Rutian. Analysis of Predictors for Immune-related Adverse Events and the Correlation with Efficacy in Progressive Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2026, 29(06): 710-717.
[2]	RUAN Wanbai, LI Junfeng, YIN Yanmei, PENG Lei, ZHU Kexiang. Research Progress of Targeted Therapy and Immunotherapy for Pancreatic Cancer [J]. Chinese General Practice, 2025, 28(23): 2950-2960.
[3]	SONG Fenfen, LI Shengmian. Real-World Study of Camrelizumab-based Regimen for Locally Advanced and Metastatic Esophageal Cancer [J]. Chinese General Practice, 2025, 28(07): 844-852.
[4]	HU Lingxi, LI Mei, FU Yiwei, LU Lixia, MA Xiaoxuan, WANG Rongqi, NAN Yuemin. The Value of Serum VEGF in Evaluating the Clinical Efficacy of TACE Alone or Combined with Target Immunotherapy in Advanced Hepatocellular Carcinoma [J]. Chinese General Practice, 2024, 27(32): 4033-4039.
[5]	YU Haibo, ZHANG Tianyu, LI Xin, ZHANG Jiajia, SHEN Man, ZHAN Xiaokai, TANG Ran, FAN Sibin, ZHAO Fengyi, HUANG Zhongxia. Efficacy and Safety of Dual-targeted Chimeric Antigen Receptor-T Cell Therapy in Patients with Refractory-relapsed Multiple Myeloma: a Meta-analysis [J]. Chinese General Practice, 2024, 27(08): 985-994.
[6]	CHEN Lulu, ZHANG Liping, LI Jingwen, DONG Wenjie, WU Xin'ai. Clinical Effect and Safety of PD-1 Inhibitors plus Fruquintinib as Later-line Treatment for Metastatic Colorectal Cancer [J]. Chinese General Practice, 2023, 26(18): 2262-2267.
[7]	Yan LI, Kunlun WANG, Hui YANG, Erjiang ZHAO, Bingxu LI, Shenglei LI, Xiaotao DONG, Ling YUAN. Prognostic Value of Lactate Dehydrogenase in Advanced Esophageal Squamous Cell Carcinoma Patients with Immunotherapy [J]. Chinese General Practice, 2022, 25(26): 3263-3269.